These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9097885)

  • 1. Role of dopamine D2, D4 and serotonin(2A) receptors in antipsychotic and anticataleptic action.
    Seeman P; Tallerico T; Corbett R; Van Tol HH; Kamboj RK
    J Psychopharmacol; 1997; 11(1):15-7. PubMed ID: 9097885
    [No Abstract]   [Full Text] [Related]  

  • 2. The D2 receptor: love it and leave it.
    Pickar D
    Mol Psychiatry; 1998 Mar; 3(2):101-2. PubMed ID: 9577830
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors.
    Seeman P; Corbett R; Van Tol HH
    Neuropsychopharmacology; 1997 Feb; 16(2):93-110; discussion 111-35. PubMed ID: 9015795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
    Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D4 receptors may alleviate antipsychotic-induced parkinsonism.
    Seeman P; Corbett R; Van Tol HH
    Adv Pharmacol; 1998; 42():478-82. PubMed ID: 9327943
    [No Abstract]   [Full Text] [Related]  

  • 8. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
    Gogos A; Kwek P; Chavez C; van den Buuse M
    J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor.
    Heuillet E; Petitet F; Mignani S; Malleron JL; Lavayre J; Néliat G; Doble A; Blanchard JC
    Eur J Pharmacol; 1996 Oct; 314(1-2):229-33. PubMed ID: 8957240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes.
    Moran-Gates T; Massari C; Graulich A; Liégeois JF; Tarazi FI
    J Neurosci Res; 2006 Aug; 84(3):675-82. PubMed ID: 16810690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Functional role of dopamine D4 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):13-20. PubMed ID: 15027326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.
    Kuroki T; Meltzer HY; Ichikawa J
    J Pharmacol Exp Ther; 1999 Feb; 288(2):774-81. PubMed ID: 9918588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
    Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
    J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
    Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
    J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
    Zhang K; Davids E; Tarazi FI; Baldessarini RJ
    Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
    Maj J; Rogóz Z; Skuza G
    J Neural Transm (Vienna); 1999; 106(11-12):1063-73. PubMed ID: 10651103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.